Uncover the hidden risks and cutting-edge advancements in HCM, ATTR-CM, and Lp(a) management at PCNA’s Cardio Connections event. This virtual summit equips you with the latest evidence-based strategies to differentiate HCM subtypes, apply targeted therapies, and assess elevated Lp(a) as a critical CVD risk factor. Elevate your nursing practice with actionable insights on symptom management, guideline-directed care, and patient-centered care approaches to improve outcomes for high-risk populations.
Agenda
| Time | Session |
|---|---|
| 9:00 AM CT | Welcome |
| 10:00 AM CT | Product Theater presented by Boston Scientific |
| 12:25 PM CT | Adjourn |
| 9:15 AM CT | Cardiac Amyloidosis (ATTR-CM): Advancing Equitable Recognition and Management Presented in partnership with the American Society of Echocardiography Jeremy Slivnick, MD, FACC, FASE, FSCMR and Morgan Lewis BSN, RN |
| 10:55 AM CT | Lp(a): Lurking Under the Surface Keith C. Ferdinand, MD, FACC, FAHA, FASH, FASPC, FNLA, FPCNA(h) |
| 11:40 AM CT | Hypertrophic Cardiomyopathy Care Evolving: From Symptom Control to Targeted Therapy Kate Lew, MSN, RN, FNP-C |
Thank you to Alnylam Pharmaceuticals, Boston Scientific, Cytokinetics, and Novartis Pharmaceuticals for their support of this program.
Learning Objectives
Hypertrophic Cardiomyopathy Care Evolving: From Symptom Control to Targeted Therapy
- Explain the pathophysiology and prevalence of HCM including differentiation between obstructive and non-obstructive HCM.
- Differentiate traditional pharmacologic and interventional HCM treatments from emerging disease-specific therapies, including mechanism of action, clinical effects, and role in symptom management.
- Apply evidence-based nursing assessment, monitoring, and patient education strategies for individuals with HCM receiving advanced pharmacologic therapies, including cardiac myosin
Lp(a): Lurking Under the Surface
- Examine Lp(a) as an independent risk factor for CVD highlighting testing strategies and urgency
- Take a deep dive into elevated Lp(a) CVD exacerbation and risk enhancement including PAD, MI, and stroke
- Review the latest guideline directed recommendations and clinical evidence for Lp(a) management
Cardiac Amyloidosis (ATTR-CM): Advancing Equitable Recognition and Management
- Recognize clinical and echocardiographic red flags of ATTR-CM across diverse populations including key signs and imaging features to differentiate from other causes
- Describe the epidemiology of ATTR-CM, including the higher varying prevalence based on ancestry, and explain how implicit bias, access barriers, and misattribution of symptoms contribute to delayed diagnosis in minority populations (including women)
- Discuss equitable, team-based strategies application of evidence-based diagnostic pathways and culturally responsive communication strategies to promote timely testing, referral, and patient engagement in diverse clinical settings.
MD, FACC, FAHA, FASH, FASPC, FNLA, FPCNA(h)
MSN, RN, FNP-C
MD, FACC, FASE, FSCMR
